Doctor's Notes

Hand Eczema Across 710 Indian Hospital Workers

Editorial illustration for Hand Eczema Across 710 Indian Hospital Workers with Dr. Arsy #003 jar; fictional educational scene, not a patient or result.

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

The question behind this paper

This review looks at hospital nursing, cleaning and auxiliary work. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.

Study snapshot

Study element Reported detail
Population 710 Indian hospital workers: 279 nurses, 246 cleaners and 185 auxiliary workers
Design Cross-sectional questionnaire and clinical severity study
Timepoint Point and one-year prevalence at the study evaluation
Key result Point prevalence was 7.2% and one-year prevalence 18.9%; mean HECSI was 9.39 and mean DLQI 5.37, with cleaners reporting greater quality-of-life impairment

How to interpret the result

Prevalence, clinical signs and quality of life capture different parts of burden. The cleaner comparison points to unequal impact, not proof that job title alone caused the difference.

Important limitation: The single-site cross-sectional design cannot establish causation, occupational groups differed in tasks and background factors, and average scores hide individual variation.

Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.

Questions a worker, family or clinician can ask next

  • What exactly was measured: reported symptoms, visible signs, allergy, sleep movement, work loss or quality of life?
  • Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
  • Did the study compare groups or follow change over time, and what factors could still explain the difference?
  • Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
  • What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?

Primary and authoritative sources

PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.

Where a cosmetic moisturizer fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.

Bottom line

The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.

← Back to Doctor's Notes